Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
ORIC Pharmaceuticals, Inc. Banner

ORIC Pharmaceuticals, Inc.

ORIC Stock Analysis

Page title

Section title

About ORIC Pharmaceuticals, Inc.

Biotechnology
Healthcare

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations...

ORIC Pharmaceuticals, Inc. Key Metrics

Market Cap
$753M
52 Weeks Low
$5.27
52 Weeks High
$16.65
P/B
2.48x
P/E
-6.78x
P/S
489.39x

Upcoming Events

    ORIC Analyst Forecasts

    ‌
    ‌

    ORIC Financials

    ORIC Income Statement Key Metrics

    • Revenue(TTM)1.54 M
    • Gross Profit(TTM)485,000
    • EBITDA(TTM)-124.59 M
    • Net Income(TTM)-110.78 M
    • EPS Diluted(TTM)-1.75

    Decode ORIC's Latest Earnings Call with Ease

    Tap 'Generate' for a crystal-clear,
    AI-crafted summary and stay ahead in the investment game!

    ORIC earnings and revenue history

    ORIC Return on Equity

    See how efficiently ORIC generates profit for it's shareholders.

    -44.94%

    10
    0
    100

    1. Poor

    2. Average

    3. Strong

    Return on Equity vs Peers

    Return on Equity ratio of ORIC (-0.449) is lower than the average of its peers (-0.369).

    Return on Equity Growth

    ORIC's Return on Equity has shown poor growth over the past 10 years, increasing by only -8.80%.

    ORIC Revenue Growth

    See how ORIC has grown it's revenue over the past 10 years.

    ‌

    Revenue Growth

    ORIC's revenue has shown poor growth over the past 10 years, increasing by only 0%.